Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AZD1222 for COVID-19 Prevention in Russia
NCT04540393Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Planned start Sep 2020; status: withdrawn.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04540393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540393.